Moreover, CSF1R inhibitor PLX3397 greatly abrogates the demyelination, loss of oligodendrocytes, and reactive astrocytosis in the cuprizone model of MS (Tahmasebi et al., 2019; Marzan et al., 2021). This evidence concerns the gene CSF1R and myeloid sarcoma.